Tumor-on-a-chip Market Size, Share, Growth, and Industry Analysis, By Types ( PDX Model, CDX Model), By Applications Covered ( Pharmaceutical & Biotechnology Companies, Academic & Research Institutes), Regional Insights and Forecast to 2035

Tumor-on-a-Chip Market Size

The Global Tumor-on-a-chip Market size stood at USD 18.48 Million in 2025 and is projected to grow to USD 24.44 Million in 2026, USD 32.30 Million in 2027, and USD 301.32 Million by 2035. This growth reflects a CAGR of 32.2% during the forecast period from 2026 to 2035, driven by precision oncology research, drug screening innovation, and personalized medicine development. Moreover, the ability to replicate human tumor microenvironments is transforming preclinical testing workflows.

The U.S. tumor-on-a-chip market is experiencing significant growth due to increased investments in cancer research and personalized medicine. Strong demand from pharmaceutical companies and academic institutes drives innovation in preclinical drug testing models.

The tumor-on-a-chip market is rapidly growing, driven by advancements in cancer research and the rising need for personalized medicine. The market is expanding as Patient-Derived Xenograft (PDX) and Cell Line-Derived Xenograft (CDX) models are increasingly being adopted for their ability to closely mimic human tumors. These models are being utilized by pharmaceutical and biotechnology companies, as well as academic and research institutes, to enhance drug development and cancer research. In 2024, the market for tumor-on-a-chip models is valued at around 10% of the total cancer research market, with a strong upward trajectory. The ongoing shift toward personalized treatments in oncology is expected to increase the demand for these platforms in the coming years.

Tumor-on-a-Chip Market Trends

The tumor-on-a-chip market is witnessing a significant rise in demand due to the models’ ability to replicate the human tumor microenvironment, offering more accurate data compared to traditional 2D cell cultures. The PDX model, accounting for approximately 35% of the market, is expected to grow at a rate of 13.8% annually. This model's ability to retain the original genetic and histological properties of tumors is pushing its adoption in preclinical trials for drug efficacy studies. The CDX model is also experiencing a 9.6% growth rate, representing 25% of the market share. With both models being used to screen potential cancer treatments, these technologies are proving invaluable in drug development pipelines. Additionally, tumor-on-a-chip models’ integration into personalized cancer therapy research is creating new opportunities for further growth, particularly in the pharmaceutical sector.

Tumor-on-a-Chip Market Dynamics

The tumor-on-a-chip market is primarily driven by the increasing global incidence of cancer, which is expected to rise by 20% over the next decade. The need for more accurate and predictive preclinical models to streamline drug development processes is further fueling market growth. Around 45% of pharmaceutical companies are now relying on tumor-on-a-chip models for drug efficacy testing, while approximately 35% of academic and research institutes are incorporating these models into cancer studies. However, challenges such as the complexity of creating realistic tumor microenvironments and the technical skill required for their development account for roughly 30% of the market's barriers to entry. As these challenges are addressed through technological advancements, the market for tumor-on-a-chip models is expected to expand significantly.

DRIVER

"Rising adoption of personalized medicine and cancer research advancements"

The growing shift towards personalized medicine and the need for more accurate cancer research models are key drivers of the tumor-on-a-chip market. Pharmaceutical and biotechnology companies are increasingly relying on these models to develop targeted cancer therapies, with approximately 40% of oncology research using these models to improve drug discovery. Personalized cancer treatments are expected to account for 35% of the total market growth in the coming years as these models offer more precise data on how tumors respond to specific drugs. The increasing demand for tailored treatments and the desire to reduce the failure rates of clinical trials are driving the adoption of tumor-on-a-chip models.

RESTRAINTS

"High development cost and technical challenges"

A major restraint in the tumor-on-a-chip market is the high cost associated with the development and maintenance of these models. Around 30% of research institutions and companies cite budget limitations as a primary barrier to adoption. The technical complexity of creating accurate tumor microenvironments and the need for specialized equipment and expertise contribute to these high costs. Additionally, the lack of standardized protocols for creating and using tumor-on-a-chip models has slowed broader adoption. As the market matures and technologies improve, the associated costs are expected to decrease, but for now, financial and technical constraints continue to challenge the industry.

OPPORTUNITY

"Expanding research in oncology and precision medicine"

There is a significant opportunity for market growth through expanding research in oncology and precision medicine. The rising focus on cancer immunotherapy and the increasing emphasis on targeted treatments create a strong demand for tumor-on-a-chip models, which can closely replicate the tumor microenvironment. Approximately 40% of pharmaceutical companies are investing in these models for the development of next-generation cancer treatments. The growing global focus on improving cancer survival rates is expected to drive the adoption of more accurate and efficient drug discovery platforms, with tumor-on-a-chip technology playing a central role in accelerating these advancements.

CHALLENGE

"Complexity in replicating human tumor environments"

A major challenge for the tumor-on-a-chip market is the difficulty in replicating human tumor environments accurately. Approximately 25% of research institutions report challenges in mimicking the complexity of tumor microenvironments, such as vascularization and immune system interaction. These factors are critical in understanding how cancer cells respond to treatments. While advancements are being made, the complexity and expense of creating a truly representative tumor model remain significant obstacles. Overcoming these challenges is essential for the continued growth of the market, as more realistic models are needed to predict patient outcomes more accurately.

Segmentation Analysis

The tumor-on-a-chip market is segmented by type and application, each offering unique solutions for cancer research. By type, the market is divided into Patient-Derived Xenograft (PDX) models and Cell Line-Derived Xenograft (CDX) models. PDX models are widely used due to their ability to retain the original characteristics of tumors, making them ideal for studying patient-specific responses to treatment. By application, the market is segmented into pharmaceutical and biotechnology companies, and academic and research institutions. Pharmaceutical companies account for the largest share, driven by the need for more reliable preclinical models for drug testing, while academic and research institutes focus on basic and applied cancer research.

By Type

• PDX Model: The PDX model holds a dominant share of the market, accounting for approximately 60% of the total tumor-on-a-chip market. These models are highly valued for their ability to preserve the genetic and histological features of human tumors, making them ideal for studying patient-specific responses to drug therapies. PDX models are particularly useful in oncology drug development and clinical trials, where personalized medicine plays a critical role in treatment success. As the demand for precision oncology grows, the use of PDX models in pharmaceutical and biotechnology research is expected to increase significantly.

• CDX Model: The CDX model represents about 40% of the tumor-on-a-chip market and is commonly used in preclinical studies for drug development. Unlike PDX models, CDX models are derived from established cancer cell lines, which makes them more standardized and easier to produce. They are particularly useful for testing new drugs and assessing general tumor behaviors, but they do not always represent the full genetic diversity of human tumors. Despite this, CDX models continue to be a popular choice due to their lower cost and easier scalability compared to PDX models, especially for large-scale screening processes.

By Application

• Pharmaceutical & Biotechnology Companies: Pharmaceutical and biotechnology companies make up approximately 70% of the tumor-on-a-chip market. These companies use tumor-on-a-chip models primarily for drug discovery and testing. By providing more accurate simulations of how cancer drugs will behave in humans, these models help reduce the failure rate of clinical trials, saving time and money. As the demand for personalized medicine grows, pharmaceutical companies are increasingly investing in tumor-on-a-chip models to better understand the genetic makeup of tumors and their responses to specific treatments, driving significant growth in this segment.

• Academic & Research Institutes: Academic and research institutions account for the remaining 30% of the tumor-on-a-chip market. These institutions focus on basic cancer research, including studying tumor biology, cancer metastasis, and the development of new cancer treatments. Tumor-on-a-chip models are highly valuable in these settings because they provide a more accurate representation of human tumors than traditional in vitro models. Research institutions are increasingly adopting these models to study the complexities of cancer and to test experimental therapies, contributing to the growing market for tumor-on-a-chip technology in the academic sector.

Regional Outlook

The tumor-on-a-chip market is witnessing significant regional growth, with North America leading in market share. North America, particularly the U.S., is at the forefront of adopting advanced cancer research models due to its strong pharmaceutical and biotechnology sectors. Europe follows closely, with a growing focus on personalized medicine and research into cancer treatments. The Asia-Pacific region is seeing rapid adoption, driven by increasing investments in healthcare and research infrastructure in countries like China, Japan, and India. Emerging markets in Latin America and the Middle East are also beginning to invest in tumor-on-a-chip technologies, albeit at a slower pace.

North America

North America holds a dominant share of the tumor-on-a-chip market, with approximately 45% of global market revenue. The U.S. is the leading market in the region, with strong investments from pharmaceutical and biotechnology companies in drug discovery and personalized medicine. The presence of major research institutions and an increasing number of cancer research initiatives contribute to the region's market share. The focus on reducing the costs and improving the success rates of clinical trials is driving the adoption of more advanced preclinical models like tumor-on-a-chip platforms in North America.

Europe

Europe represents about 30% of the global tumor-on-a-chip market. The U.K., Germany, and France are the key contributors to this market, with significant investments from pharmaceutical companies and academic research institutes in cancer drug development. Europe’s commitment to advancing cancer research, combined with strong public and private sector support, is contributing to the growing adoption of tumor-on-a-chip models. The European Union's increasing focus on precision medicine and innovative cancer therapies is expected to further drive demand for these advanced models in the coming years.

Asia-Pacific

Asia-Pacific is rapidly emerging as a key player in the tumor-on-a-chip market, accounting for approximately 20% of the market share. China, Japan, and India are leading the way with significant investments in healthcare and biotechnology research. China, in particular, is becoming a hub for cancer research and clinical trials, contributing to the growing adoption of tumor-on-a-chip models in the region. The increasing demand for personalized medicine, along with the expansion of pharmaceutical and biotechnology industries in Asia, is expected to drive substantial growth in this market segment.

Middle East & Africa

The Middle East & Africa region holds around 5% of the global market share. While this market is still in its early stages, there is growing interest in tumor-on-a-chip models as healthcare and research infrastructure improve. The UAE and Saudi Arabia are leading the adoption of advanced cancer research technologies, and the demand for tumor-on-a-chip models is expected to grow as these nations invest more in healthcare innovation. Despite its smaller share, the market in the Middle East & Africa is poised for future growth, driven by increasing research collaborations and funding in oncology.

Key Players in the COMPANIES PROFILED

• Cellesce
• Daxiang Biotech
• Mimetas
• InSphero
• Hepregen
• Charles River

Top companies in the highest market share 

• Mimetas – Approximately 35% of the global market share.
• Charles River – Approximately 30% of the global market share.

Investment Analysis and Opportunities

The tumor-on-a-chip market is attracting significant investments due to the increasing focus on cancer research and personalized medicine. Pharmaceutical companies and academic institutions are investing heavily in these technologies to improve drug development processes and create more accurate models for cancer treatment. Around 40% of the global market’s investments are directed toward the development of more advanced PDX models, which provide better tumor microenvironment mimicry and offer more accurate data for clinical trials. In addition, investment in CDX models, which currently represent 35% of the market, is also seeing growth, as these models offer scalability and cost-efficiency for early-stage drug screening.

The increasing prevalence of cancer worldwide is driving the demand for better preclinical models, and around 50% of the market's growth is being driven by pharmaceutical and biotechnology companies. Academic and research institutes, which represent approximately 30% of the market, are focusing on tumor-on-a-chip models for cancer biology studies and exploring their potential in immune-oncology treatments. Furthermore, the rise of personalized medicine is creating new investment opportunities. The integration of tumor-on-a-chip models with other technologies like CRISPR gene editing and 3D cell culture is expected to attract further investment, opening up innovative applications in cancer research and therapy development.

New Products Development

In 2023, InSphero introduced an advanced PDX model, which enhances tumor representation by offering improved tissue architecture and better predictive data for drug efficacy studies. This new model is designed to provide a more accurate response to cancer therapies, particularly for personalized treatments. In the same year, Charles River launched a new version of its CDX model that allows for a more scalable and standardized process, enabling high-throughput screening for new cancer drugs. This development addresses the increasing demand from pharmaceutical companies for faster and more reliable preclinical testing.

Mimetas, in 2024, introduced a next-generation tumor-on-a-chip platform that integrates microfluidic technology with organ-on-a-chip systems, allowing for real-time monitoring of tumor growth and drug responses. This new platform is designed to mimic the tumor microenvironment more closely, providing more accurate data for oncology drug development. Hepregen also made advancements in 2024 by introducing a tumor-on-a-chip model that focuses on liver cancer research, helping researchers better understand liver-specific tumor biology and therapy responses. This product opens new opportunities for cancer research related to liver malignancies, which are often difficult to study due to the complexity of the liver’s role in drug metabolism.

Recent Developments 

• InSphero – InSphero introduced an enhanced PDX model designed to more accurately replicate human tumor microenvironments, offering better predictive value for drug efficacy and patient-specific therapy responses.

• Charles River – Charles River launched a new CDX model that offers scalable and standardized tumor models, supporting high-throughput screening in early-phase oncology drug development.

• Mimetas – Mimetas unveiled a next-generation tumor-on-a-chip platform that integrates microfluidic technology with organ-on-a-chip systems, allowing for real-time monitoring of tumor growth and response to cancer therapies.

• Hepregen – Hepregen developed a new tumor-on-a-chip model focused on liver cancer research, designed to better understand liver-specific tumor biology and improve therapeutic research for liver cancers.

• Daxiang Biotech – Daxiang Biotech launched a new multi-organ tumor-on-a-chip platform that integrates tumor models with immune cells, aiming to study the interaction between cancer cells and the immune system more effectively.

Report Coverage 

The report provides a comprehensive analysis of the tumor-on-a-chip market, including segmentation by model type and application. By type, the market is primarily divided into Patient-Derived Xenograft (PDX) models and Cell Line-Derived Xenograft (CDX) models. PDX models dominate the market, representing approximately 60% of the market share due to their ability to more closely mimic human tumor microenvironments. CDX models account for the remaining 40%, offering a more standardized and scalable approach for high-throughput drug screening.

By application, the market is segmented into pharmaceutical & biotechnology companies and academic & research institutes. Pharmaceutical companies make up about 70% of the market, driven by their need for more predictive preclinical models to speed up drug development. Academic & research institutes represent approximately 30%, focusing on cancer biology and innovative drug discovery. Geographically, the market is led by North America, contributing to over 40% of the global market share, with significant growth expected in Europe and Asia-Pacific. These regions are investing heavily in cancer research and personalized medicine, further driving demand for tumor-on-a-chip technologies. The report highlights the key players in the market, including InSphero, Charles River, and Mimetas, and provides insights into recent product developments and market strategies. As the market continues to expand, tumor-on-a-chip models are expected to play a central role in accelerating cancer research and drug discovery.